ArticleDiscover nano2025
Xanthatin nanocrystals exert anti-inflammatory properties against TNFα-primed 2D monolayers and in 3D spheroids of human HT29 colorectal cancer cells.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poor water-solubility of emerging new chemotherapeutic drugs lead to low absorption and tissue bioavailability. Improved drug delivery has therefore recently been achieved through the versatile physico-chemical properties of nanocrystals (NCs) in targeted cancer therapies. Here, nanocrystalization was used with xanthatin, a not highly water-soluble natural sesquiterpene lactone compound that possesses anti-tumour properties and which was recently investigated for potential use in the treatment of cancer and autoimmune diseases. Given that tumour-promoting inflammation is a hallmark of colorectal cancer (CRC), and that epidemiological studies associated inflammatory biomarkers to CRC poor prognosis and therapy resistance, the anti-inflammatory properties of xanthatin NCs were assessed in 2D monolayers and in 3D spheroids of a human HT29 CRC cell model. The 3D spheroids being a model recapitulating a cancer stem cells and chemoresistant phenotype. HT29 2D monolayer cell response was first tested against four pro-inflammatory inducers including phorbol-12-myristate-13-acetate, tumour necrosis factor alpha (TNFα), transforming growth factor beta, and Concanavalin A. Of these inducers, HT29 cell response to TNFα resulted in the most elevated expression of cyclooxygenase (COX)-2 which was prevented by commercial xanthatin along with the phosphorylation of the extracellular signal-regulated kinase 1/2 and of IkappaB (IκB). Alteration of 3D spheroids formation and of the inflammatory/immunity transcriptomic signature was also found better altered by xanthatin NCs in comparison to commercial xanthatin and the isolated molecule. Collectively, our data indicate that xanthatin nanocrystallization did not alter the potential in vitro anti-inflammatory and anticancer properties of xanthatin against a 3D CRC chemoresistance cellular model. These properties make NCs a significant advancement in the field of cancer theranostics to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.